Mpox (monkeypox) vaccination recommendations
Recommendations for the use of pre- and post-exposure vaccination during an mpox incident.
Applies to England
Documents
Details
This document includes information on:
- pre-exposure vaccination for occupational exposure
- post-exposure vaccination
- vaccine prescribing and administration
- consent and record forms
- Imvanex® patient information leaflet
Further mpox guidance is also available, including information on case definitions and contact tracing.
Updates to this page
Published 20 May 2022Last updated 20 November 2024 + show all updates
-
Guidance withdrawn.
-
Added version 12, removed appendices 2 to 5.
-
Updated to include the use of intradermal administration for pre and post-exposure use in healthy adults, limiting post-exposure vaccination to children under 5 and immunosuppressed individuals, during periods of limited supply, and further clarification on vaccine eligibility for occupational exposure.
-
Updated guidance, version 10.
-
Version 9: updated background and added a link to classification of contacts (appendix 6), along with advice for vaccination and follow-up.
-
Updated appendix 6 to clarify recommendations for PEP after 14 days since last exposure.
-
Updated guidance, version 7.
-
Updated guidance, version 6.7.
-
Added links to additional monkeypox guidance.
-
First published.